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Abstract
Background: Mesenchymal stem cells (MSC) are promising candidates for cell therapy, as they migrate to areas of injury,
differentiate into a broad range of specialized cells, and have immunomodulatory properties. However, MSC are not
invisible to the recipient’s immune system, and upon in vivo administration, allogeneic MSC are able to trigger immune
responses, resulting in rejection of the transplanted cells, precluding their full therapeutic potential. Human
cytomegalovirus (HCMV) has developed several strategies to evade cytotoxic T lymphocyte (CTL) and Natural Killer (NK)
cell recognition. Our goal is to exploit HCMV immunological evasion strategies to reduce MSC immunogenicity.
Methodology/Principal Findings: We genetically engineered human MSC to express HCMV proteins known to
downregulate HLA-I expression, and investigated whether modified MSC were protected from CTL and NK attack. Flow
cytometric analysis showed that amongst the US proteins tested, US6 and US11 efficiently reduced MSC HLA-I expression,
and mixed lymphocyte reaction demonstrated a corresponding decrease in human and sheep mononuclear cell
proliferation. NK killing assays showed that the decrease in HLA-I expression did not result in increased NK cytotoxicity, and
that at certain NK:MSC ratios, US11 conferred protection from NK cytotoxic effects. Transplantation of MSC-US6 or MSC-
US11 into pre-immune fetal sheep resulted in increased liver engraftment when compared to control MSC, as demonstrated
by qPCR and immunofluorescence analyses.
Conclusions and Significance: These data demonstrate that engineering MSC to express US6 and US11 can be used as
a means of decreasing recognition of MSC by the immune system, allowing higher levels of engraftment in an allogeneic
transplantation setting. Since one of the major factors responsible for the failure of allogeneic-donor MSC to engraft is the
mismatch of HLA-I molecules between the donor and the recipient, MSC-US6 and MSC-US11 could constitute an off-the-
shelf product to overcome donor-recipient HLA-I mismatch.
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Introduction
Mesenchymal stem cells (MSC) are promising candidates for use
in cellular replacement therapies, since they have the inherent
ability to migrate to areas of inflammation and injury and
participate in tissue repair [1,2,3,4]. This beneficial effect is due to
MSC’s ability to differentiate into several different cell types, to
release soluble factors that inhibit apoptosis and promote healing,
and to stimulate and/or support resident stem/progenitor cells
[5,6,7,8]. Another advantage of MSC over other putative stem
cells is that MSC can be harvested using straightforward
procedures, and expanded in vitro to obtain large numbers of
cells, without losing their original potential. Besides their pro-
liferation and differentiation potentials, MSC have also shown
immunomodulatory capabilities at multiple levels. In vitro studies
demonstrated that MSC express intermediate levels of HLA class I
and lack expression of HLA class II and other co-stimulatory
molecules, resulting in immune evasion during allogeneic trans-
plantation [9]. Moreover, MSC were shown to inhibit pro-
liferation of natural killer (NK) cells, T and B lymphocytes, and
impair dendritic cell maturation during in vitro assays
[10,11,12,13,14,15]. In vivo, when systemically administered,
MSC have been shown to extend survival of skin allografts in
baboons [16], and are able to ameliorate graft-versus-host disease
(GVHD) in human patients [17].
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provided evidence that MSC are not invisible to the recipient’s
immune system, and that upon in vivo administration, MSC are
able to trigger immune responses, resulting in rejection of the
transplanted cells [18,19,20,21,22]. These studies showed that one
of the major factors responsible for the failure of donor MSC to
engraft is the mismatch of HLA class I molecules between the
donor and the recipient [18,19,23]. Furthermore, using a rhesus
macaque model, Isakova et al. demonstrated that allogeneic MSC,
upon intracranial injection, were able to induce an immune
response that was dependent on cell dose and the degree of donor-
host HLA-I mismatch. This study also showed that the immune
response was mediated by NK and cytotoxic T cells [24].
Therefore, for those instances in which transplant timing or
underlying disease preclude the use of autologous MSC, it is
imperative to find ways to overcome donor-recipient HLA-I
mismatch, so that the full therapeutic benefit from allogeneic MSC
transplants can be achieved. One possible approach would be to
engineer MSC in such a way that the expression of HLA-I
molecules would be decreased or absent. This would allow the
generation of an ‘‘off-the-shelf’’ universal donor MSC that could
serve as an immediate source of cells to anyone in need, and would
also thwart high costs of a personalized MSC therapy.
Human cytomegalovirus (HCMV), a virus ubiquitously present
in humans, has developed several strategies to evade cytotoxic T
lymphocyte (CTL) and NK cell recognition [25,26,27,28]. HCMV
avoids CTL attack by producing proteins, coded for by the unique
short (US) region of the genome, that downregulate HLA-I surface
expression by different mechanisms. US2 and US11 proteins
induce translocation of HLA class I heavy chains from the
endoplasmic reticulum (ER) to the cytosol, where they are
degraded by the proteasome. US3 protein retains HLA class I
molecules inside the ER, while US6 protein prevents peptide
translocation and loading onto the HLA class I molecules
[29,30,31].
In this study, we genetically engineered MSC to express each of
these US proteins, in order to determine which one would be able
to better downregulate HLA-I expression, and thus shield MSC
from CTL attack. It is important to note that failure to engage
class I inhibitory receptors on the NK cells by putative target cells
can lead to increased susceptibility of these cells to NK cell lysing.
Therefore, we also investigated whether preventing MSC HLA-I
expression by US proteins would lead to enhanced NK killing of
the MSC. Here we report that MSC engineered to express US6
(MSC-US6) or US11 (MSC-US11) exhibited the most pronounced
reduction in HLA-I surface levels, and decrease in human and
sheep lymphocyte proliferation, while NK killing assays showed
that MSC-US11 were protected from NK cytotoxic effects. Using
the fetal sheep as a model of human stem cell transplantation, we
have previously reported on the ability of human-derived MSC to
engraft and generate hepatocytes [5,32]. In this model, both CTL
and NK-like cells are present in circulation at the time of
transplant, but the immune system is still immature, allowing for
the engraftment of human cells without additional manipulation
[33]. In the present studies, we used human hepatocyte formation
in fetal sheep as a paradigm to investigate whether the expression
of US6 or US11 on MSC would allow higher levels of
engraftment, and differentiation into liver-specific cell types. Our
results show that expression of US6 or US11 proteins significantly
increased the engraftment of human MSC in the fetal sheep liver,
and that donor-derived MSC could still be reprogramed into
human hepatocyte-like cells. Since one of the major factors
responsible for the failure of allogeneic-donor MSC to engraft is
the mismatch of HLA-I molecules between the donor and the
recipient [18,19,23,34], MSC-US6 and MSC-US11 could consti-
tute an off-the-shelf product to overcome donor-recipient HLA-I
mismatch.
Results
HCMV US proteins down-modulate HLA-I expression on
MSC
MSC were transduced with different MSCVneo retroviral
vectors expressing US2, US3, US6 or US11, as described in detail
in the material and methods section. Non-transduced MSC, or
MSC transduced with an empty MSCVneo retroviral vector
(MSC-E) were used as controls (Figure 1A). At 48 hrs after
transduction, stable US recombinant MSC were selected with
500 mg/ml G418 for 5 days, replacing the selection media every
two/three days. Therefore, only cells that expressed neomycin
resistance (NeoR) survived the selection process. Transduced
MSC, after selection, were analyzed for expression of the
respective US transcripts as well as the presence of the NeoR
antibiotic resistance/selection marker. Using PCR and the primers
shown in Table 1, we determined that the majority of the
transduced cells expressed the corresponding US gene and the
antibiotic resistance/selection marker NeoR. Since the expression
of each US gene was driven by the MSCVneo 59LTR, similar
transcription levels of different US genes were attained (Figure 1B).
The morphology of the transduced MSC remained similar to
that of non-transduced MSC (Figure 1C), and all US-transduced
cells showed comparable ability to differentiate into adipocytes or
osteocytes as untransduced MSC or MSC transduced with empty
retrovirus (MSC-E) (Figure 2A and B). Furthermore, all MSC
populations remained undifferentiated if not stimulated with
external agents and they all continued to express cell surface
markers such as CD29, CD90 and CD105.
We then analyzed, by flow cytometry, expression of HLA-I in
US-transduced MSC, MSC-E and non-transduced MSC. A
representative panel of the results obtained with three independent
experiments is shown in Figure 3 A and B, which depicts the
percentage of HLA-I positive MSC after subtracting the isotype
control. Figure 3C summarizes the percentage of HLA-I positive
cells obtained in 3 independent experiments, and Figure 3D
shows, for the same experiments, the different Median Fluorescent
Intensity (MFI) Ratios for US-transduced MSC, MSC-E and non-
transduced MSC. MFI ratio was obtained by dividing HLA-I’s
MFI by the respective isotype’s MFI. Transduction of MSC with
MSCVneo empty retroviral vector resulted in a decrease in the
percentage of transduced cells expressing HLA-I, from
20.9861.36% to 15.3460.73% (p.0.01). A non-statistically
significant reduction of the MFI ratio was also observed. Before
transduction, overall HLA-I MFI ratio was 3.4960.17 and after
transduction with the empty retroviral vector, the MFI ratio
became 2.6560.07 (p.0.01). However, transduction with recom-
binant retrovirus expressing either US2 or US3 resulted in
a statistically significant reduction in HLA-I levels, when
compared to both untransduced MSC or MSC-E. US2 caused
a 60% reduction in the percentage of cells expressing HLA-I,
(6.0560.38%) (p,0.01) and a significant reduction in MFI ratio
(1.7660.02) when compared to MSC-E (p,0.01) and untrans-
duced MSC (p,0.01). US3 decreased the percentage of cells
expressing HLA-I by 62% (5.8360.43%) (p,0.01) and a decrease
in MFI ratio to 1.3960.04 (p,0.01). US11 was even more
efficient than US2 and US3 in reducing HLA-I expression, and
was able to diminish the number of positive cells by 85% when
compared with MSC-E (MSC-US11 HLA-I: 2.2460.47%,
(p,0.01); MFI ratio: 0.8460.2, (p,0.01)). US6 HCMV protein
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36163Figure 1. Generation of US-transduced MSC. (A) HCMV US2, US3, US6 and US11 cDNA sequences were cloned into the pMSCVneo plasmid
between EcoRI and XhoI or Sal-I. US genes were driven by the MSCV LTR promoter while the Neomycin resistance marker gene (NeoR) was under the
control of an internal PGK promoter. (B) Total RNA was extracted from each of the transduced and untransduced MSC populations and, after reverse
transcription, cDNAs were obtained and amplified using specific primers for each of the US genes, NeoR and B-Actin. (C) Light microscope image at
106original magnification of the different MSC populations showing similar morphology during cell culture. Images were captured with an Olympus
IX-71 microscope.
doi:10.1371/journal.pone.0036163.g001
Table 1. PCR primers for testing US-transduced and untransduced MSC.
Primer Name F/R
a Sequence (59 to 39) Product sizes (Bp)
US2 F Eco F ATAGAATTCA-ATGAACAATCTCTGGAAAGC 600
US2 R-Sal I R ATTGTCGAC-TCAGCACACGAAAAACCG
US3 F-EcoRI F ATAGAATTCAA-ATGAAGCCGGTGTTGG 561
US3 R-Xho I R GCGCTCGAG-TTAAATAAATCGCAGACGG
US6 F-EcoRI F AAGGAATTC-ATGGATCTCTTGATACGTCTCGG 552
US6 R-Xho I R ATTCTCGAG-TCAGGAGCCACAACGTCG
US11 F-EcoRI F TAAGAATTCA-ATGAACCTTGTAATGCTT 648
US11 R-Xho I R TATCTCGAG-TCACCACTGGTCCG
Neomycin F F GTGGAGAGGCTATTCGGCTA 481
Neomycin R R CCTTGAGCCTGGCGAACAGT
b-actin F F ACTCCTGCTTGCTGATCCAC 474
b-actin R R TGGCTACAGCTTCACCACC
aF, Forward Primer; R, Reverse Primer.
doi:10.1371/journal.pone.0036163.t001
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HLA-I expression on MSC, when compared to MSC-E, with only
1.4060.06% (p,0.01) of MSC-US6 expressing HLA-I and a MFI
ratio of 0.7060.006 (p,0.01). When the effect of US6 on
percentage of cells expressing HLA-I was compared to that of
US2, US3, and US11, a statistically significant difference was
found between US6 and the two former transduced MSC
(p,0.01), but not the latter (p.0.01). Also, there was not
a statistically significant difference between MSC-US6 MFI ratio
and MSC-US11 MFI ratio (p,0.01).
Expression of HCMV US proteins on MSC decreases
peripheral blood mononuclear cell (PBMNC) proliferation
Several studies demonstrated that MSC alone are able to
suppress PBMNC proliferation [9,10,11,15]; however, recent
reports showed that allogeneic MSC can be rejected by CTL
and that one of the major factors is the mismatch of HLA class I
molecules between the donor and the recipient [18,19,23].
Therefore, we hypothesized that the decrease in HLA-I expression
induced by US HCMV proteins would lead to reduction of
PBMNC proliferation when in the presence of allogeneic MSC.
PBMNC proliferation values obtained by co-culturing PBMNC
with allogeneic MSC were arbitrarily set as 1. Proliferation values
for PBMNC when in the presence of MSC-US and MSC-E were
then re-calculated, within the same experiment, by expressing
these values as a ratio of the set value of 1 for PBMNC co-cultured
with untransduced allogeneic MSC. The results of these experi-
ments (n=4) are shown in Figure 4A. Although transduction of
MSC with the empty retroviral vector caused a decrease in human
PBMNC proliferation (MSC vs. MSC-E; 1 vs. 0.8060.03;
p,0.01), this effect was far more pronounced when MSC were
transduced with vector encoding US proteins 2, 6 and 11. When
compared with MSC-E, the expression of US2 and US3 on MSC
reduced human PBMNC proliferation by 22.5% (from 0.80 to
0.6260.05; p,0.01) and 11% (from 0.80 to 0.7160.03; p.0.01)
respectively, while expression of US11 and US6, decreased
PBMNC proliferation by 39% (0.4960.09; p,0.01) and 55%
(0.3660.04; p,0.01). Furthermore a direct correlation was found
between the levels of HLA-I and human PBMNC proliferation
(Figure 4B).
Since sheep was used as the in vivo model to study engraftment of
human MSC transduced with US proteins, we also analyzed the
effect of each one of these cell populations on the induction of
sheep PBMNC proliferation (Figure S1). The values for sheep
PBMNC proliferation were obtained in a similar way to those for
human PBMNC proliferation. Transduction of MSC with empty
retrovirus reduced, but not significantly, PBMNC proliferation
(MSC vs. MSC-E; 1 vs. 0.8660.07; p.0.01). Also, expression of
US2 or US3 did not decrease sheep PBMNC proliferation when
compared to MSC or MSC-E (1.0160.11; 1.0560.11; respec-
tively) (p.0.01). However, expression of US6 or US11 by MSC
significantly reduced sheep PBMNC proliferation when compared
to MSC-E, 30% and 27% respectively (0.5660.06 (p,0.01) and
0.5860.07 (p#0.01)).
Figure 2. US transduced MSC possess the same differentiative capacities as untransduced MSC. (A) Adipocytic differentiation of
transduced and untransduced MSC. Lipid vacuoles were observed by red staining and nuclei by blue staining. (B) Osteogenic differentiation of
transduced and untransduced MSC. Red staining indicated alkaline phosphatase activity, blue staining the nuclei, and black staining the calcium
deposits. All images were captured with an Olympus IX-71 microscope at 406original magnification.
doi:10.1371/journal.pone.0036163.g002
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cell lysis
There have been controversial reports regarding whether
reduction in HLA-I expression by HCMV US proteins renders
infected cells more susceptible to NK killing [35,36]. Therefore,
we wanted to determine whether engineering MSC to express
lower levels of HLA-I resulted in higher susceptibility of these cells
to NK lysis. We thus analyzed the effect of expressing the HCMV
US proteins on NK cell recognition, activation and killing of
MSC. NK cell cytotoxicity assays (n=6) were performed as
described in the material and methods section, and the results are
depicted in Figure 5. NK killing assays were performed using the
interleukin-2 independent cell line NK-92MI. This cell line,
derived from NK-92, was used due to its high proliferation rate in
cell culture, and high cytotoxic properties in the absence of IL2.
The NK-92MI cell line is similar to activated NK cells in terms of
surface receptor expression and functional properties, but it lacks
expression of the KIR receptor of the p58 complex, which is an
inhibitory receptor for HLA-C [37,38]. Analysis of HLA-C surface
levels showed that the percentage of positive cells expressing HLA-
C was almost neglible, 1.360.2% in untransduced MSC, and
0.760.2% and 0.760.3% for MSC-US6 or MSC-US11 re-
spectively. Therefore, the interaction between inhibitory receptor
KIR and MSC, independently of using primary NK cells or NK-
92MI, does not occur due to absence of HLA-C on MSC. NK-
92MI also lacks the CD16 receptor, which is required for
antibody-dependent cellular cytotoxicity [37,38]. Since the NK
killing assays performed in this study did not require antibody-
dependent cellular cytotoxicity activity of the NK cells, the NK-
92MI cell line constituted an appropriate tool for testing
susceptibility of US-transduced MSC to NK cytolysis.
Results from NK killing assays demonstrated that transduction
with an empty retrovirus did not result in statistically significant
reduction of NK killing-mediated lysis of MSC, when compared to
untransduced MSC for most of the ratios NK:MSC analyzed
(Figure 5). At a 20:1 effector:target (NK92-MI:MSC) ratio, the
percentage of specific lysis of untransduced MSC was 90.5069.5%
and of MSC-E 68.9363.92% (p.0.05). Between MSC expressing
Figure 3. HCMV US proteins down-regulate HLA-I surface expression on MSC. (A) MSC, MSC-E, MSC-US2, MSC-US3 and MSC-US6 were
analyzed for HLA-I surface expression by flow cytometry. Panel A shows the results of a representative experiment from at least 3 independent
studies. (B) MSC and MSC-US11 were analyzed for HLA-I surface expression by flow cytometry. Panel B shows the results of a representative
experiment from at least 3 independent studies. The percentage of HLA-I positive cells was calculated by subtracting background fluorescence as
determined by staining with the respective isotype control. (C) Average of the percentage of HLA-I positive cells in 3 independent experiments, and
(D) respective Median Fluorescence Intensity ratio as determined by flow cytometry. MFI ratio (MFI cell population/MFI cell population isotype). The
results are shown as mean6 SEM (* indicates p,0.01 when comparing the transduced MSC with untransduced MSC and MSC-E population).
doi:10.1371/journal.pone.0036163.g003
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lower than MSC-E (p,0.05). In MSC-US2, NK cell-mediated
lysis was 37% less than that of MSC-E. NK killing-mediated lysis
of MSC-US2 was 43.5969.43% (p,0.05), that of MSC-US3 was
45.6067.76% (p,0.05), and that of MSC-US11 was
45.5262.43% (p,0.05). Furthermore, at this ratio of 20:1,
expression of US6 on MSC did not result in a significant reduction
of NK killing (60.3765.77) when compared to MSC-E. When the
effector:target ratio was 10:1, US2 expression reduced NK cell
lysis by 35% and US11 by 26%, when compared to MSC-E (%
specific lysis: 23.1964.82% ( p,0.05); 26.3361.95% ( p,0.05) vs.
35.4562.40%). However, at this ratio, neither MSC-US3
(28.9064.4%) nor MSC-US6 (30.1065.6%) produced a statisti-
cally significant reduction in NK–mediated lysis compared to
MSC-E. At a ratio of 5:1, the ability of NK-92MI cells to target all
of the US transduced MSC was not statistically different from
MSC-E; however, at this ratio, MSC-US2, MSC-US6 and MSC-
US11 had a statistically significant reduced NK–cell mediated lysis
compared to untransduced MSC (Figure 5). At a ratio of 1:1 the
overall ability of NK-92MI cells to target MSC was similar
amongst all the MSC tested.
These results show that the decrease in HLA-I expression
following the transduction of MSC with retroviral vectors
encoding US6 or US11 does not increase the ability of NK cells
to target these cells as compared to normal MSC. Moreover, at
E:T ratios higher than 5:1, expression of US proteins on MSC, in
particular US11, led to an increased protection of MSC against
NK cell lysis.
HLA-E and HLA-G1 expression levels are similar between
cells expressing US6 or US11 and the MSC-E cell line
Since we showed that US6 and US11 protected MSC from NK
killing despite the downregulation of HLA class I expression, we
next investigated which molecules could be mediating transduced
MSC protection from NK lysis. HLA-E is a non-classical HLA-I
molecule, and a specific ligand for the NK cell inhibitory receptor
CD94/NKG2. Although it has been reported that during CMV
infection HLA-E expression is not affected by HCMV US11 or
Figure 4. Expression of HCMV US proteins by MSC decreases PBMNC proliferation and correlates with the levels of HLA-I. (A) Each of
the transduced and untransduced MSCs were used as stimulators and were co-cultured with responders human PBMNC. After five days, DNA
synthesis was assayed with the BrdU cell proliferation colorimetric ELISA. Data represents mean 6 SEM of four independent experiments. In each
experiment the specific stimulator-responder co-culture was performed in triplicate (* indicates p,0.01 and were considered statistically significant
compared to MSC-E levels). (B) Furthermore a direct correlation was found between the levels of HLA-I MFI and human PBMNC proliferation.
doi:10.1371/journal.pone.0036163.g004
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true when these individual HCMV proteins were intentionally
over-expressed on MSC. Therefore, using flow cytometric
analysis, we investigated whether HLA-E expression on MSC-
US6 or MSC-US11 could be mediating protection against NK
lysis. The percentage of positive HLA-E cells for non-transduced
MSC was almost negligible (0.3560.03%, MFI ratio: 0.8460.02).
Furthermore, the percentage of positive cells or MFI ratio for
HLA-E expression did not change after expressing US6 (% of
MSC-US6 0.16760.003%, MFI ratio 1.0060.06) or US11
proteins (MSC-US11 0.5160.12%, MFI ratio 0.92260.007).
Next, we studied expression of HLA-G1, another non-classical
HLA-I molecule, whose interaction with inhibitory receptors
found on NK cells, such as ILT2 and ILT4 leads to the inhibition
of NK- and T-cell activation programs. Studies using flow
cytometry demonstrated that untransduced MSC expressed
HLA-G1 protein constitutively (MFI ratio: 1.3660.03;
11.5360.7%) and that transduction of MSC with empty retrovirus
or retrovirus expressing US11 protein did not significantly modify
surface levels of HLA-G1 (MFI ratio: 1.8360.02 for MSC-E;
1.4360.13 for MSC-US11), but increased the percentage of cells
that were expressing HLA-G1. The percentage of MSC-US11
positive cells for HLA-G1 was 17.0561.65%, similar to that of
MSC-E (18.7961.71%). The percentage of MSC-US6 expressing
HLA-G1 was less than for all the other cells (6.4560.97%)
(p,0.05), but a slight increase in HLA-G1 surface levels was seen
when compared to those of MSC-E (MFI ratio: 2.3160.29 vs.
1.8360.02) (p.0.05).
Expression levels of several NK activating ligands are
similar between MSC-US6, MSC-US11 and MSC-E
Since the cytolytic capability of NK cells depends on the
balance between activating and inhibitory signals on the target
cell, we next investigated whether there were differences in the
expression of known activating NK cell ligands on the surface of
untransduced MSC, MSC-US6, and MSC-US11 (n=3). Using
antibodies specific for the NKG2D ligands, ULBP 1, 2 and 3, we
were able to determine, in 3 different experiments, that the
percentage of MSC, MSC-US6, and MSC-US11 expressing these
molecules was almost negligible. Only 0.560.2% of MSC
expressed ULBP1, 0.0860.02% ULBP2, and ULBP3 was absent
on MSC. In similarity, only a very small percentage of MSC-US6
and MSC-US11 expressed ULBP1 (0.860.07 and 1.960.02
respectively) and ULBP2 (0.160.01 and 0.0760.02), and none
expressed ULBP3.
We also studied other NKG2D ligands MICA/B (n=3), and
only 1.760.06% of MSC, 3.360.1% of MSC-US6 and 1.760.03
of MSC-US11 were positive for these molecules, demonstrating
that these ligands do not play an important role in the MSC/NK
interaction.
We next looked for the presence of the DNAM-1 ligands,
CD112 and CD155, on the surface of the different MSC
populations. Flow cytometric analysis demonstrated that both
transduced and untransduced MSC were negative for CD112. By
contrast, CD155 was expressed on 18.1%62.1 of untransduced
MSC (MFI ratio: 4.6960.07), on 21.99%60.96 of MSC-E (MFI
ratio:4.2460.05), and on 22.160.8% of the MSC-US11 (MFI
ratio:4.2560.09). A higher percentage of MSC-US6 expressed
CD155 (3760.7%) when compared to both MSC and MSC-E
(p,0.05). The MFI ratio of MSC-US6 was also increased when
compared to the same populations (5.3660.08) (p,0.05).
Since it has also been reported that the ability of NK to kill
CMV-infected cells depends on the elevated levels of expression of
CD58 on the surface of infected cells and not on the down-
regulation of cell surface Class I HLA [35], we also investigated
whether transducing MSC to express US6 and US11 resulted in
modification of CD58 expression on cell surface. CD58 was not
expressed by untransduced MSC, MSC-US6 or MSC-US11 (data
not shown).
Figure 5. Expression of HCMV US proteins protects MSC against NK cell lysis. Stimulators, MSC-E, MSC-US2, MSC-US3, MSC-US6, MSC-US11
and untransduced MSC were co-cultured independently with different concentrations of NK-92MI cells at 20:1, 10:1, 5:1 and 1:1 effector:target ratios
for 4 hrs. Release of lactate dehydrogenase was measured after cell lysis by ELISA. The percent specific lysis was calculated for each cell population
and effector:target ratio. The percentage of spontaneous lysis for all of the MSC tested in cytotoxicity assays ranged from 0.3–9.09%. Data represents
the mean 6 SEM of 6 independent experiments for each ratio between NK92MI cells and each transduced and untransduced cell line. (* indicates
statistically significant difference between % specific lysis of US transduced MSC and MSC-E).
doi:10.1371/journal.pone.0036163.g005
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US11 proteins
Although MSC do not usually express HLA-II molecules [9],
several studies have shown that when these cells are exposed to
certain growth factors [39] or pro-inflammatory cytokines such as
Interferon-gamma [40], induction of HLA-II occurs in MSC.
Therefore, we next examined the effect of forced expression of
US6 or US11 proteins on HLA-II regulation within MSC. As
determined by flow cytometric analysis, transduction of MSC with
MSCVneo retroviral vectors over-expressing US6 or US11 did not
cause a statistically significant difference in HLA-II expression
when compared with control MSC. As previously reported, MSC
did not express HLA-II, with HLA-II MFI not differing from that
of the isotype control (MFI ratio:1.3060.14). In similarity, the
levels of HLA-II expression, as determined by MFI ratio, on MSC-
US11 (MFI ratio: 1.0660.01) and MSC-US6 (MFI ra-
tio:1.2360.04), were similar to or lower than the MFI ratio of
non-transduced MSC, demonstrating that up-regulation of HLA-
II did not occur after engineering of the MSC with US proteins.
Transplantation of human MSC-US6 and MSC-US11 in
fetal sheep results in higher levels of liver cell
engraftment when compared with MSC-E as determined
by quantitative PCR (qPCR)
We have previously shown that human MSC engraft in the liver
of fetal sheep after in utero transplantation [5,32]. Therefore we
tested the ability of transduced cells that had provided the best
immunological results in vitro, MSC-US6 and MSC-US11, to
engraft and generate hepatocyte-like cells, and compared them to
control MSC-E. To this end, we transplanted 61 day-old pre-
immune fetal sheep recipients (n=6) via intraperitoneal route with
MSC-US6, MSC-US11, or MSC-E and compared their levels and
patterns of engraftment. At 127 days of gestation (term of 145
days), animals were euthanized and analyzed for liver engraftment.
Figure 6. Quantification of Human MSC engraftment in fetal sheep liver. (A) Standard curve for human GAPDH amplification. Different Ct
values were obtained by amplification of GAPDH at different percentages of human MSC/(human MSC+sheep MSC cells) concentrations. qPCR
reaction for each concentration was repeated three times. (B) Percentage of total human cells engrafted in fetal liver of sheep that were injected with
different MSC. The results are mean 6 SEM of twelve replicates of qPCR reactions for MSC-E and MSC-US6 transplanted animals or six replicates of
qPCR reactions for MSC-US11 transplanted animals. (C) Representative immunofluorescence staining and confocal microscopy of NPT-II and albumin
staining of liver sections from sheep receiving MSC-US6 cell line. Images were captured using a Fluoview 1000 confocal microscope with a 406
objective. The white arrow marks the area of the inset. Scale bars: 50 mm main picture; 12.5 mm on inset (D) (top) on the left, quantification of total
NPT-II positive cells in fetal liver of sheep that were injected with the different MSC cell lines. On the top right, quantification of dual NPT-II and
albumin positive cells in fetal liver of animals that were injected with the different MSC cell lines. On the bottom left, quantification of dual NPT-II and
alpha-fetoprotein positive cells in fetal liver of sections from animals that were injected with the different MSC. On the bottom right, quantification of
dual NPT-II and Hepar-I positive cells in fetal liver of sheep that were injected with the different MSC cell lines. The results are means 6 SEM of at least
90,000 cells that were counted for NPT-II staining within the fetal liver sections from sheep that were injected with the different MSC. * p,0.05.
doi:10.1371/journal.pone.0036163.g006
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engraftment within the liver of the sheep that received each of the
different MSC-US cells, we performed human-specific qPCR as
described in detail the Material and Methods section. First, as
shown in Figure 6A we constructed a calibration curve using
different ratios of human MSC/total cells (0.0001, 0.001, 0.005,
0.01, 0.05, 0.1, and 0.2), and their corresponding Ct values
(28.076, 26.093, 22.449, 19.218, 18.759, and 18.637). We then
performed qPCR using DNA extracted from the livers of the
transplanted animals and GAPDH human specific-primers. We
used the obtained Ct values to extrapolate the percentage of
human MSC engraftment within the liver sample from each of the
MSC-transplanted animals. As can be seen in Figure 6B, fetal liver
from sheep injected with MSC-E cells exhibited human MSC
engraftment levels of 7.0260.81%. In the animals that received
MSC expressing US6 protein, the levels of human MSC
engraftment were 10.8061.23%, corresponding to a 1.5-fold
increase in engraftment (p,0.05). In similarity, MSC-US11 had
engraftment levels of 12.3760.57% within the fetal liver,
corresponding to a 1.8-fold increase over the engraftment seen
with MSC-E (p,0.05). There was no significant difference in
levels of engraftment within the fetal sheep liver when comparing
cells expressing US6 to those expressing US11 (p.0.05). These
results demonstrate that forced expression of US6 or US11 on
human MSC increased their ability to engraft within the fetal
sheep liver following in utero transplantation. Another possible
explanation it would be that MSC-US6 or -US11 upon
engraftment proliferated more than the MSC-E control. Although
MSC-US6 or -US11 did not show increased proliferation rates in
vitro (data not shown), it is also possible, but not likely, that higher
levels of engraftment were due to higher MSC-US6 or -US11 cell
proliferation upon in vivo lodging.
Immunofluorescence analysis with an anti-neomycin
phosphotransferase II antibody confirms enhanced
engraftment of MSC-US11 and MSC-US6 in fetal sheep
liver
Human MSC engraftment within the liver of the transplanted
animals was also analyzed by using an antibody against the vector-
encoded marker, neomycin phosphotransferase II (NPT-II). Liver
samples collected from sheep that received the various MSC lines
were cryopreserved, and processed as described in the Materials
and Methods section. Engrafted human MSC were localized and
quantified by staining with an antibody to the NPT-II marker gene
contained within the MSCV vector, as shown in figure 6C (middle
panel) and D. NPT-II staining on liver from fetal sheep that
received MSC-E revealed 5.360.4% NPT-II positive cells. In
animals that received MSC-US6 and MSC-US11, the percentages
of NPT-II+ cells were 12.860.9% and 14.760.8%, respectively,
which corresponds to a 2.4 and 2.8-fold increase in engraftment
over that achieved with MSC-E. The enhanced engraftment
produced by US proteins was, in both cases, statistically significant
compared to the engraftment produced by MSC-E (p,0.01). In
similarity to the results obtained with qPCR, the difference in
engraftment capabilities of MSC-US6 and MSC-US11, was not
statistically significant (p.0.05), but in both analyses animals
receiving MSC-US11 had higher levels of engraftment.
MSC expressing US HCMV proteins are able to
differentiate in vivo in hepatocyte-like cells after
engraftment within the fetal liver
Since we have previously shown that transplantation of human
MSC into fetal sheep also results in formation of donor-derived
hepatocytes [5,32], here we investigated whether modifying MSC
with the US proteins would alter the differentiative capacity of
these engrafted MSC. Therefore, we performed dual immunoflu-
orescence staining for NPT-II and albumin. NPT-II staining
unequivocally identified the human MSC that had engrafted
within the sheep liver, as described above, while albumin labeling
identified both human and sheep albumin-producing hepatocytes
(Figure 6C left panel). As can be seen shown in Figure 6C (right
panel), human MSC reprogramed to a hepatocyte-like phenotype,
as evidenced by colocalization of NPT-II and albumin staining.
Quantitation of the percentage of NPT-II/albumin-positive cells
within liver sections from fetal sheep that had received each of the
three different human MSC lines is shown in Figure 6D. MSC-E,
MSC-US11 and MSC-US6 generated 0.2360.02%, 0.2860.04%
and 0.2860.02% of NPT-II/albumin-positive cells respectively.
Analysis of NPT-II and alpha-fetoprotein dual-positive cells,
demonstrated that transduced MSC engrafted and generated
primitive hepatocyte-like cells. Specifically, in the presence of US6
or US11 protein, 0.2160.03% and 0.2360.03% of the liver cells
were also NPT-II-Alpha fetoprotein-positive, respectively. MSC-E
generated less NPT-II-Alpha fetoprotein-positive cells
(0.1760.02%) when compared to that of either the MSC-US6
or MSC-US11 (Figure 6 D).
We next analyzed liver sections from sheep transplanted with
the different recombinant MSC using an anti-Hepar-I antibody.
Quantification of dual-positive cells in liver sections from animals
transplanted with MSC-E cells showed that 0.2060.03% of the
cells were NPT-II+, Hepar+ (Figure 6D). In animals transplanted
with MSC-US6 protein, 0.3460.02% liver cells were dual-positive
for NPT-II and Hepar-I (p,0.05 compared to MSC-E engraft-
ment), and similarly, following transplantation with cells expres-
sing US11, 0.3060.03% of the cells within the recipient liver were
expressing both markers (p,0.05 compared to MSC-E engraft-
ment). However, there was not a statistically significant difference
in the percentage of Hepar positive cells between MSC-US6 and
MSC-US11 (p.0.05).
Discussion
Despite numerous studies reporting the efficacy of allogeneic
MSC as therapeutic tools (reviewed in [41]), controversy still
remains whether these cells, upon transplantation, are able to elicit
an immune response in the recipient, lessening their therapeutic
potential when compared with their autologous counterpart.
MSC, regardless of graft source, possess the same immunomod-
ulatory and anti-inflammatory properties. This is due, at least in
part, to the antiproliferative effects of MSC on immune and other
somatic cells, leading to arrest of cell division in T and NK cells,
and thwarting cytokine secretion and cytotoxicity [42]. Still,
allogeneic MSC are not invisible to the immune system, and
several studies have demonstrated that administration of allogeneic
MSC induced immunogenic responses, and that MSC were
recognized and rejected by the immune system [2,18,19,43]. Since
MSC express negligible amounts of HLA-II, but display variable
levels of HLA-I on their surface, and harbor several ligands to
activating NK cell receptors [44,45], it is likely that MSC can
become a target of NK and CTL.
Here, we genetically engineered MSC to express the HCMV
proteins US2, US3, US6 and US11, since these proteins were
previously shown to reduce HLA-I surface levels on somatic cells.
Moreover, this reduction in HLA-I levels prevented CTL
recognition, activation and killing of infected cells during a normal
HCMV infection [30,31], and of breast and neuronal cells when
these cells were transfected with these HCMV US genes and
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our results show that MSC transduced with retroviral vectors
expressing HCMV proteins US2, US6 and US11 reduced levels of
HLA-I on their surface, when compared with non-transduced
MSC, or with MSC transduced with a retroviral vector encoding
only the NeoR gene. Furthermore, we demonstrated that US6 and
US11 were the most efficient in downregulating expression of
HLA-I and therefore reducing MSC immunogenicity, as demon-
strated by the correlation between HLA-I expression and the
decrease in human PBMNC proliferation using MLR assays.
MSC-US6 produced the greatest reduction of HLA-I expression,
decreasing MFI by 90%, and the most pronounced decrease in
human (61%) PBMNC stimulation as well as sheep (35%)
PBMNC stimulation. The differences in the ability of the various
US proteins to reduce HLA-I expression on MSC are in
agreement with previous studies using other cell types [48,49],
and are most likely due to the distinctive mechanism by which
each of the proteins are known to down-regulate MHC-I
molecules [50,51,52]. Furthermore, they are also in conformity
with what has been reported by others demonstrating that US11 is
more effective in degrading class I molecules [53,54].
Because reduction of HLA-I molecules usually renders cells
susceptible to NK lysis, and since in an allograft setting NK cells
are frequently recruited to the site of the transplant and contribute
to graft rejection [55,56], it was our concern that down-regulation
of HLA-I expression on MSC would lead to an increased
susceptibility of MSC to NK lysis. Here we show that the
expression of US proteins on MSC, and consequent HLA-I down-
regulation, did not increase their susceptibility to NK killing, and
that US2, US3 and especially US11-transduced MSC were
protected from NK cytotoxic effects at certain NK: MSC ratios.
Although MSC used in this work were not of adult origin, and it
has been reported that fetal and adult MSC differ in their
interactions with NK cells, both fetal and adult MSC are
susceptible to lysis by activated NK cells [45]; therefore, we
anticipate that the transduction of adult MSC with US proteins 2,
3, or 11 could also be successfully used in adult MSC to avoid
CTL and NK activation and decrease killing of transplanted
allogeneic cells.
In order to start dissecting possible mechanisms by which US
proteins enable NK killing evasion, we studied the surface levels of
several activating (ULBP 1, 2 and 3, MICA/B, CD112 and
CD155) and inhibitory ligands (HLA-E and HLA-G1), as well as
CD58 molecules (higher levels of which are linked to enhanced
NK killing), on all the MSC populations. HLA-E, a non-classical
HLA-I molecule and a specific ligand for the NK cell inhibitory
receptor CD94/NKG2, was expressed at very low levels or absent
in all of the MSC populations, and the same was found for the
activating NKG2D ligands ULBP1–3 and MICA/B, the DNAM-
1 ligand CD112, and CD58. Therefore, none of these molecules
seem to play a role in this particular case of MSC/NK interaction.
The absence of these stimulatory molecules provides a possible
explanation for the lack of NK killing in the absence of HLA-I
expression. Prior studies have shown that even though many
circulating cells lack inhibitory receptors, they do not attack
normal tissues [57]. Likewise, red blood cells [58] and neural stem
cells [59] are not lysed by NK cells, despite expressing no HLA-I.
This is presumably due to the requirement for activating signals to
initiate NK lysis. This is agreement to what has been reported for
bone marrow derived MSC, in which CD112, MICA/B, and
ULBP1–3 have been shown to be expressed and to enable NK-
mediated lysis [11].
HLA-G1, another non-classical HLA-I molecule, has been
shown to be constitutively expressed by MSC [60,61,62], and
interaction of this molecule with the NK inhibitory receptors ILT2
and ILT4, leads to the inhibition of NK- and T-cell activation
programs [63,64]. Our results also showed that US-transduced
MSC cell lines expressed HLA-G1 protein at similar levels to
MSC-E. Analysis of CD155, a DNAM-1 activating ligand,
revealed that MSC constitutively express the marker, and that
CD155 expression was up-regulated on MSC-US6 when com-
pared to MSC, MSC-E and MSC-US11. Still, MSC-US6 were as
susceptible to NK killing as MSC-E and no more so than
untransduced MSC, even though MHC-I surface molecules on
MSC-US6 were significantly reduced when compared to both cell
populations.
Because NK killing assays were performed using the interleukin-
2 independent cell line NK-92MI and not primary cells, it could
be possible that different results would be obtained if we had used
the latter. However, this is highly unlikely, since NK-92MI was
used due to its high cytotoxic properties in the absence of IL2, and
because MSC lack the ligands for the few receptors that are
different between primary cells and NK-92MI. Also, the results
presented here demonstrating that, at low NK-to-MSC ratios, the
ability of NK to kill both transduced and untransduced MSC is
diminished, are in agreement with others that showed this same
effect, and that both IFN-gamma and IL-10 were involved in the
mechanism of regulating NK function [65]. However, this
mechanism does not explain the decrease in NK cytotoxicity
towards MSC transduced with US 2,3 and 11 at ratios of 20:1 and
10:1, and does not concur with a study which demonstrated that
down-regulation of MHC-I expression rendered the cells suscep-
tible to NK cells when transplanted in a xenograft model [66].
However, since our results were obtained with in vitro assays and in
the other study the results were obtained after in vivo trans-
plantation, it is difficult to directly compare the seemingly
conflicting results.
Therefore, we used human hepatocyte formation in fetal sheep
as a paradigm to investigate whether MSC-US6, that confers
higher protection against CTL proliferation but same NK killing
protection as MSC-E; and MSC-US11, that grants higher
protection against both CTL proliferation and NK killing
compared to MSC-E cell line, would allow higher levels of
engraftment and differentiation into liver-specific cell types when
compared to MSC-E. Analysis of hepatic engraftment of MSC
expressing US6 or US11 proteins using PCR and immunofluo-
rescence for the vector-encoded NeoR gene product, NPT-II,
revealed that over-expression of US6 and US11, regardless of the
difference in NK killing protection, resulted in higher levels of
engraftment when compared to MSC-E. Expression of US6 and
US11 resulted in a 1.5- and 1.8-fold increase in the levels of liver
engraftment, respectively when compared to MSC-E.
Moreover, transduction of MSC with US6 and US11 did not
result in alteration of MSC reprograming into hepatocyte-like cells
as we had previously described as assessed by immunostaining
with antibodies against human albumin, HEPAR-I and alpha-
fetoprotein.
In conclusion, we found a potential strategy that allows MSC to
evade immunological rejection in mismatched recipients. This
approach maximized MSC engraftment in a xenogeneic model
and could, in an allogeneic transplantation setting, allow curative
numbers of cells to engraft and fulfill their role at the site of injury
thereby improving their therapeutic benefit.
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Mesenchymal Stem Cells
Mesenchymal stem cells were obtained from at least 5 different
donors as previously described [8] using anti-Stro-1 antibody
(R&D Systems, Minneapolis, MN) and magnetic cell sorting
(Miltenyi Biotec, Inc., Auburn, CA) to isolate Stro-1+ cells. Stro-
1+ cells were then cultured in gelatin (Sigma, St Louis MO) coated
flasks and MSCGM
TM (Mesenchymal Stem Cell Growth Medium
BulletKitH, Lonza, Walkersville, Maryland, USA).
NK 92-MI cells were obtained from American Type Culture
Collection (ATCC, Rockville, MD), and were maintained in
Alpha MEM (Invitrogen, Carlsbad, CA) supplemented with 2 mM
L-glutamine (Invitrogen) 1.5 g/l sodium bicarbonate, 0.2 mM
inositol, 0.1 mM 2-mercaptoethanol, and 0.02 mM folic acid, (all
from Sigma), 12.5% FBS (Atlanta biologicals), and 12.5% horse
serum (Atlanta biologicals).
Construction of recombinant vectors
US2, US3, US6, and US11 DNA sequences were PCR
amplified from a clinical HCMV isolate (kindly provided by Dr.
Stephen St. Jeor, University of Nevada, Reno, Nevada, USA),
introducing EcoRI and XhoI restriction sites for US3, US6 and
US11 and EcoRI and SalI for US2 (primer sequences are shown in
Table 1). The purified PCR products were then ligated into the
pMSCV-Neo retroviral vector backbone (Clontech, Mountain
View, CA) that had been previously digested with EcoRI and XhoI.
These recombinant plasmids were transformed into One Shot
Top10 chemically competent cells (Invitrogen), and transformed
Top10 cells were selected with ampicillin 50 mg/ml (Sigma).
Positive clones were confirmed by PCR using primers for the US
insert, miniprep digestions and sequencing. For US3, US6 and
US11 cloning, digestion was performed with EcoRI and XhoI
restriction enzymes. For US2 cloning, EcoRI and BglII restriction
sites were digested, as US2 cloning generated a SalI/XhoI hybrid
restriction site.
Establishment of retrovirus-producing cell lines
Each US recombinant plasmid and an empty plasmid were
transfected into the RetroPack
TM PT67 Packaging Cell Line
(Clontech) using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Stable transfectants were selected for
5 days with 500 mg/ml G418 (Fisher), starting at 72 hrs after the
transfection. Supernatants were collected and filtered with 0.2 mm
low binding protein-syringe filters (Pall Corporation, Ann Arbor,
MI).
Transduction of MSC
Subconfluent cultures of MSC were transduced for 6 hours with
filtered supernatant containing either US recombinant or empty
MSCVneo retrovirus diluted in serum-free QBSF60 medium
(Quality Biological, Gaithersburg, MD) and 8 mg/mL protamine
sulfate (Calbiochem, San Diego, CA). After transduction, cell
layers were washed and media was changed to MSCGM
TM
(Lonza). At 48 hrs after transduction, stable US-recombinant
MSC were selected with 500 mg/ml G418 (Fisher Scientific,
Rochester, NY) for 5 days, replacing the selection media every
two/three days. Therefore, after the antibiotic selection all the
cells were transduced and consequently expressing NeoR and the
corresponding US HCMV gene. Transduction of MSC with
empty retrovirus or retroviruses coding for US genes were
performed several times with similar efficiency. Stably transduced
cells were analyzed for transgene expression and designated as
MSC-US2, MSC-US3, MSC-US6 and MSC-US11 according to
the HCMV US protein that they expressed, or the lack thereof
(MSC-E). Transmitted light images of transduced and untrans-
duced MSC populations were captured with an Olympus IX-71
microscope with a 106and 406objective. Also, total RNA was
purified from each of the transduced and untransduced MSC
using TRIzolH Reagent with the PureLink
TM RNA Micro Kit
(Invitrogen) and DNase-treated with RQ1 RNase-Free DNase
(Promega, Madison WI). In order to analyze presence/absence of
NeoR and the corresponding US gene expression, 200 ng of each
RNA sample was used for cDNA synthesis using the SuperScript
III first-strand synthesis system and random primers (Invitrogen)
according to the manufacturer’s protocol. For PCR, the reaction
mixture consisted of 1.5 mM MgCl2, 20 mM Tris-HCl (pH 8.3),
50 mM KCl, 0.2 mM dNTP mixture, 0.02 U of Taq DNA
recombinant polymerase (Invitrogen), 0.004 mg/ml of each primer
(sequences shown in Table 1) and 5 ml of cDNA. The
amplification conditions were initial denaturation at 94uC
(3 minutes), followed by 30 cycles of denaturation at 94uC
(45 seconds), annealing at 55uC (30 seconds), elongation at 72uC
(1 minute 30 seconds), and a final elongation of 10 minutes at
72uC. The PCR products were electrophoresed on a 1% agarose
gel in 16 Tris-acetate-EDTA buffer visualized by UV trans-
illumination (Biospectrum) and recorded using visionWorksLS
software.
Adipogenic and osteogenic differentiation of transduced
and untransduced MSC
MSC, MSC-E, MSC-US2, MSC-US3, MSC-US6 and MSC-
US11 were induced into adipocytes and osteocytes as previously
described [5]. After 10 days in culture adipocytic induced cells
were fixed with 10% formalin and 60% ethanol and stained with
Oil Red O 0.5% solution (Poly Scientific R & D Corp, Bay Shore,
NY) for 5 min and Hematoxylin (Sigma) for 10 min. Lipid
vacuoles were observed by red staining and nuclei by blue staining.
Cells induced to a osteocyte phenotype were fixed after 2 weeks in
culture with 95% ethanol and stained with alkaline phosphatase
(Sigma) and Fast Violet B solutions (Sigma) for 2 hours at RT and
hematoxylin for 10 minutes. Red staining indicated alkaline
phosphatase activity and blue staining the nuclei. Calcium deposits
were stained with 2.5% silver nitrate for 60 min at RT and finally
with sodium carbonate formaldehyde solution for 2 minutes.
Calcium deposits were visualized as black spots.
Flow cytometry analysis
MSC, MSC-E, MSC-US2, MSC-US3, MSC-US6 and MSC-
US11, prior to confluency, were detached by cell scraping in 16
PBS, in order to preserve extracellular epitopes. Cells were then
counted and their viability checked using Trypan Blue reagent
(Amresco, Solon OH). All the cells were more than 99% viable.
1610
5 cells were incubated for 15 min at RT with mouse anti-
human HLA-ABC PE (Becton Dickinson, Pharmingen, San Jose,
CA) or mouse IgG1 PE [clone G46-2.6] (BD Bioscience, San Jose,
CA) as isotype control. Moreover, MSC, MSC-US6 and MSC-
US11 cells were stained with mouse anti-human HLA-E [clone
MEM-E/08] (Abcam, Cambridge, MA), mouse anti-human HLA-
G FITC [clone MEM-G/9](ABD Serotec) and mouse anti-human
HLA DR, DP, DQ FITC [clone TU ¨39] (BD Bioscience). The
same cell lines were stained with the appropriate isotype control
Ab: goat anti-mouse IgG FITC (BD Bioscience) for HLA E
staining, mouse IgG1 FITC (ABD Serotec) for HLA-G staining,
and mouse IgG2a FITC (AbD Serotec) for HLA class II staining.
To test mesenchymal markers on US transduced and untrans-
duced cells, we used mouse anti-human CD29 FITC (Biosource)
[clone B-D15), mouse anti-human CD105: FITC (ABD Serotec)
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gen) [clone 5E10]. Isotype control for CD29 staining was mouse
IgG2a FITC (BD Bioscience) and isotype controls for CD90 and
CD105 staining were mouse IgG1 FITC (R&D systems). Other
antibodies used were: anti-human CD155 FITC, CD112 and
MICA/MICB FITC (AbD Serotec, Oxford, UK); anti-human
ULBP-1 PE, ULBP-2 PE, and ULBP-3 (R&D Systems Inc.,
Minneapolis, Minnesota, USA) and anti-human CD58 PE (BD
Biosciences, San Jose, US). Secondary antibody used for CD112,
and ULBP3 antibodies was goat anti mouse IgG FITC (BD
Biosciences, San Jose, US). In all the cases, viable cells were
incubated for 15 min with each antibody, washed, fixed with 0.1%
azide in PBS, centrifuged and fixed with 1% formaldehyde. A
FACSort system (Becton Dickinson) with CELLQUEST software
(Becton Dickinson) was used to analyze stained cells. Forward and
side-scatter plots were used to exclude the few dead cells and
debris from the histogram analysis plots.
Preparation of Peripheral Blood Mononuclear Cells
(PBMNC)
Human PBMNC were prepared from freshly collected,
heparinized whole blood samples from different individuals, kindly
provided by United Blood Services (Sparks Center, NV). Sheep
PBMNC were isolated from different whole blood animal samples.
Whole human or sheep blood was diluted 1:2 with IMDM and
mononuclear cells were obtained by performing Ficoll-Hypaque
density gradient (1.077 g/mL) (Sigma) centrifugation and washed
in IMDM with penicillin (100 U/mL), streptomycin (100 mg/mL)
and amphotericin B (0.25 mg/mL) (Gibco Laboratories, Grand
Island, NY USA) before and after treatment with RBC lysis buffer
(155 mM NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA). Mono-
nuclear cells were resuspended in DMEM (Gibco) with 10% FBS
and counted using capillary pipettes (BD Unopette).
Mixed Lymphocyte Reaction
MSC, MSC-E, MSC-US2, MSC-US3, MSC-US6 and MSC-
US11 were used as stimulator cells and PBMNC from human or
sheep blood were used as responder cells. Prior to the experiment,
each stimulator cell line was counted and its cell viability was
assessed by trypan blue dye exclusion. 10
4 cells of each stimulator
cell line were plated in triplicate into a 96-well flat-bottom plate
(BD Falcon) containing MSCGM
TM and incubated until con-
fluency was reached. They were then treated with 5 mg/ml
mitomycin C (Roche Applied Science) at 37uC for 2.5 hrs in
humidified incubator with 5% CO2 to prevent further pro-
liferation. After incubation, cells were washed three times with
IMDM. A co-culture was then made in triplicate by adding 1610
5
responder cells to each well, with a final volume of 0.1 ml of 10%
FBS DMEM. The final MSC/PBMNC ratio per well used in this
assay was approximately 1610
4/1610
5=1/10 in accordance with
the recommendations of the BrdU cell proliferation colorimetric
ELISA (Roche) technical bulletin.
Several controls were performed: media control and stimulator
and responder controls, which contain either stimulator or
responder cells alone. Cultures were incubated for 5 days at
37uCi n5 %C O 2 and 100% humidity. On the fifth day, BrdU
(Roche, Mannheim, Germany) was added to each well to a final
concentration of 10 mM. After incubation for 6 to 12 hrs at 37 C
in 5% CO2 and 100% humidity, DNA synthesis was assayed with
the BrdU cell proliferation colorimetric ELISA, (Roche) according
to the manufacturer’s instructions. A background control, which
consists of incubating unlabeled stimulator cells with antibody
against BrdU, was also performed. Newly synthesized BrdU-DNA
was quantitated using a microplate reader (Bio-Rad, Hercules,
CA).
NK cytotoxicity assay
MSC, MSC-E, MSC-US2, MSC-US3, MSC-US6, MSC-US11
(1610
5 cells/ml; 50 mL/well) in a flat-bottomed 96-well micro-
plate (BD Falcon) were incubated in triplicate with different





5 cells/ml; 50 mL/well) in Alpha MEM
complete media without phenol red (Gibco). All cells were
previously assessed for cell viability. The cytotoxicity tests were
run at 20:1, 10:1, 5:1 and 1:1 E:T ratios following the guidelines of
the CytoTox 96H Non-Radioactive Cytotoxicity Assay (Promega).
The plate was centrifuged and incubated at 37uC for 4 hrs. Target
cell maximum release was obtained by incubating each cell
population with 9% Triton solution for 45 min at 37uC. The plate
was centrifuged again and 50 mL of each supernatant was
transferred to another flat bottom 96 well microplate containing
50 mL of substrate mix. Absorbance at 490 nm due to lactate
dehydrogenase release was evaluated using a microplate reader
(BioRad). Several controls were performed: (1) effector and target
spontaneous controls, which contained of either effector or target
cells alone; and (2) culture media background control. Culture
medium background absorbance was subtracted from all absor-
bance values of Experimental, Target Cell Spontaneous Release,
and Target Maximum Release. The percentage of specific lysis
was calculated for all the different NK-MSC ratios as: Percent
specific lysis=[ (experimental release2target spontaneous re-
lease)/(target maximal release2target spontaneous release)]6100.
Transplantation of human MSC into fetal sheep
recipients
MSC-E, MSC-US6 and MSC-US11 were cultured as pre-
viously described. A total of 5.6610
4 cells from each of the
different MSC populations were injected in 0.4 ml of a QBSF60
serum-free medium (Quality Biologicals, Gaithersbrug, MD) into
the peritoneal cavity of 61 day-old pre-immune fetal sheep
recipients (term of 145 days) by ultrasound-guided injection with
a transabdominal ultrasound apparatus (ALOKA SSD-100)
outfitted with a 5-MHz probe. Each transduced MSC cell line
was transplanted into two fetuses. At 66 days after transplantation,
the animals were euthanized, and their tissues collected. Liver
tissues were then analyzed for the presence of human donor cell
engraftment, with MSC-E transplanted animals serving as
controls. All sheep received humane care, and all the procedures
were performed according to protocols approved by the In-
stitutional Animal Care and Use Committee at the University of
Nevada Reno (Protocol number 00314).
Quantitative real time PCR to assess human engraftment
To perform the calibration curve for absolute qPCR, human
MSC and sheep MSC were trypsinized and counted with Trypan
Blue reagent (Amresco Inc., Branded Products Group, Solon,
OH). Human and sheep MSC were then combined in different
ratios to create a standard curve of samples with the following
human cell concentrations: 0.01%, 0.1%, 0.5%, 1%, 5%, 10%
and 20%, with a total of 2610
6 cells per each ratio. DNA from
each cellular dilution was extracted, as was DNA from pure
human MSC and pure sheep MSC (to serve as controls), using
DNeasy blood and tissue kit (Qiagen Valencia, CA) according to
the manufacturer’s instructions. To perform the standard curve for
GAPDH amplification and to detect human GAPDH copy
numbers in the recipient tissues, we performed a 30 ml reaction
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(SABioscience, Frederick, MD, USA), 0.2 mM GAPDH primers
and 0.5 mg of each DNA. DNA was amplified in a MicroAmpH
Optical 96-Well Reaction Plate using an Applied Biosystems Prism
7500 Fast Real-Time PCR System. After denaturizing at 95uC for
10 min, DNA products were amplified with 40 cycles, each of
which consisted of denaturation at 95uC for 15 s, followed by
annealing-extension at 60uC for 1 min. Quantitative measure-
ments of GAPDH DNA were performed by kinetic PCR using
SYBRH Green as fluorescent dye and ROX as passive reference
dye. The accumulating DNA products were monitored by the
ABI7500 sequence detection system (Applied Biosystems), and
data were stored continuously during the reaction. The results
were validated based on the quality of dissociation curves and
good amplification efficiency of the primer. DNA was extracted
from the collected liver tissues and each sample was analyzed in six
replicates along with non-template controls to monitor for
contaminating DNA. For each target tissue, the relative human
GAPDH gene copy number was normalized with human GAPDH
copy number obtained with DNA extracted from the liver of
animals that received MSC-E cells, and was then analyzed by the
2-DDCT method [67]. Each Ct value, obtained from human
GAPDH DNA amplification for each recipient animal, was used
to extrapolate from the standard curve the absolute human cell
concentration for that animal.
Tissue fixation and cryopreservation
Collected liver tissues were immersed in ice-cold PBS, washed
three times and then immersed in 4% paraformaldehyde in PBS
for 1 hour at 4uC. Subsequently, they were incubated in increasing
sucrose concentrations in PBS (5%, 10%, 15%, and 20%),
incubating for 30 min at 4uC for each sucrose concentration.
Finally, the tissues were incubated in 2 parts 20% sucrose in PBS,
one part OCT compound (Ted Pella, Inc. Redding, CA) and for
1 hour at 4uC with rocking and were then frozen in a cryomold,
using liquid nitrogen-cooled isopentane.
Detection of human engraftment by
immunofluorescence
Frozen liver tissues were sectioned at a thickness of 8 mm using
a cryostat and frozen sections were placed on microscopy slides. In
order to stain the slide with immunofluorescence antibodies,
frozen sections were first washed with 16 PBS at 4uC for three
times, for five minutes each time. Non-specific binding sites within
the tissues were then blocked by incubating the slides with 10%
NGS, 1% BSA in 16PBS for 1 hour at 4uC. Slides were washed
twice for 5 minutes each with 2% NGS in 16PBS. Sections were
then incubated overnight at 4uC with primary antibody diluted
appropriately in a solution consisting of 2% NGS in 16PBS. After
incubation with primary antibody, slides were washed three times,
for 5 minutes each, in order to remove non-specifically bound
primary antibody. The washing solution contained 2% NGS,
0.05% Triton in 16PBS, followed by a last wash with only 2%
NGS in 16PBS. An appropriate fluorescently-labeled secondary
antibody (5 mg/ml) was then added to the slides diluted in 2%
NGS in 16 PBS, and slides were incubated for 1 hour at 4uC.
Finally, slides were washed twice with 2% NGS in 16PBS three
times, for five minutes each, followed by a last wash with 16PBS
at 4uC. A couple of drops of DAPI (Biogene Ltd, Cambs, United
Kindom) were added for 15 minutes to counterstain the nuclei
within the section, followed by a wash with 16PBS. Slides were
then coverslipped with Cytoseal 60 (Thermo Fisher Scientific
(NYSE: TMO)). Primary antibodies used for this study were the
following: for NPT-II staining, rabbit anti-Neomycin Phospho-
transferase II (NPT-II) (CR1112RP-500 ul) (Fitzgerald Industries
International, MA, USA); for albumin staining, monoclonal anti-
human serum albumin (clone hsa-9) (A2672); for Hepar-I staining,
mouse monoclonal antibody (clone: OCH1E5) (Dako), and for
Alpha fetoprotein staining, mouse monoclonal anti-human alpha 1
Fetoprotein antibody (Abcam). Secondary antibodies were the
following: Alexa FluorH 594 goat anti-rabbit IgG (A-11012) (Gibco
– Invitrogen, Carlsbad, CA) and Alexa FluorH 488 goat anti-
mouse IgG (A-11001) (Gibco – Invitrogen, Carlsbad, CA). Images
from each slide were taken using a Fluoview 1000 confocal
microscope with a 406 objective (Olympus, Tokyo, Japan).
Images were taken as z-stacks with 8–10 slices per image and
then projected as 2-D images. Images were then processed using
Adobe Photoshop. Sections from each tissue were stained with
secondary antibody alone as negative control staining in all
experiments.
Statistical analysis
Experiments were independently repeated at least three times.
Results are presented as mean6 SEM. Unpaired two-tailed
student T test and one-way ANOVA were used to analyze the
statistical significance of the results; p values,0.05 were consid-
ered to be statistically significant. The Pearson correlation
coefficient (R
2) and the one-tailed p-value for the correlation
coefficient were calculated to determine the correlation and
significance, between human PBMNC proliferation and HLA-I
MFI levels on the different MSC populations. p values,0.05 were
considered to be statistically significant.
Supporting Information
Figure S1 Expression of HCMV US proteins by MSC
decreases PBMNC proliferation. Each of the transduced and
untransduced MSCs were used as stimulators and were co-
cultured with sheep PBMNC responders. After five days, DNA
synthesis was assayed with the BrdU cell proliferation colorimetric
ELISA. Data represents mean 6 SEM of four independent
experiments. In each experiment the specific stimulator-responder
co-culture was performed in triplicate (* indicates p,0.01 and
were considered statistically significant compared to MSC-E levels.
(TIF)
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